1. Epidemiological, diagnostic, therapeutic, and prognostic aspects of pf essential thrombocythemia in a retrospective study of the GIMMC group in 2000 patients;Gugliotta;Blood,1997
2. Therapeutic dilemmas: Balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD);Murphy;Thromb Hemost,1997
3. Second malignancies in patients with essential thrombocythemia treated with busulfan and hydroxyurea: Long-term follow-up of a randomized clinical trial;Finazzi;Br J Haematol,2000
4. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function;Barbui;Eur J Cancer Clin Oncol,1983
5. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia;Cortelazzo;J Clin Oncol,1990